1. Ashbee H, Gilleece M. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplant. 2011;47(7):881–94.
2. VFEND® I.V. (voriconazole) for injection, VFEND® tablets (voriconazole), VFEND® (voriconazole) for oral suspension [US physician prescribing information]. Roerig Division of Pfizer Inc, New York (NY). Revised 2008 Mar [cited 2008 Sep 3]. http://www.media.pfizer.com/files/products/uspi_vfend.pdf . Accessed 18 Jan 2010.
3. Briefing document for voriconazole (oral and intravenous formulations).Prepared for submission to US Food and Drug Administration, Food and Drugs Advisory Committee. Pfizer; 2001 Oct 4 [cited 2008 Sep 3]. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf . Accessed 18 Jan 2010.
4. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006;27(4):274–84.
5. Langman L, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem. 2007;40(18):1378–85.